Leuprolide acetate (Fensolvi®, Lupron Depot-PED®, Lupron Depot®) Non-oncology

Covers leuprolide acetate (Fensolvi, Lupron Depot‑PED, Lupron Depot) for specified non‑oncology indications—central precocious puberty, gender‑dysphoria/gender‑incongruence, uterine fibroids, abnormal uterine bleeding (Lupron Depot only), premenstrual disorders (Lupron Depot only), endometriosis, and preoperative hematologic improvement for fibroid‑related anemia; oncology uses are excluded. Approvals require indication‑specific documentation, age limits (Fensolvi ≥2 years for CPP; Lupron Depot ≥18 years for PMDs), prior therapy trials when specified (e.g., SSRI or combined oral contraceptive for PMDs; contraceptive/progestin/GnRH agent for endometriosis), prescriber or endocrinology/transgender‑care consultation for gender‑related use, and are limited to specified durations (Fensolvi/Lupron Depot‑PED 12 months; Lupron Depot 3–12 months depending on indication).

"Central precocious puberty (CPP)"